Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Everolimus in Advanced Carcinoid Tumors
NCT03950609Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2019
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, everolimus in Carcinoid Tumor (CT), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2019; status: active, not recruiting.
02
Drugs
lenvatinibeverolimus
03
Conditions
Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NCT03950609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950609.